P/E ratio for NewAmsterdam Pharma Company (NAMS)
P/E ratio at the end of 2022: -10.6
According to NewAmsterdam Pharma Company's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.9525. At the end of 2022 the company had a P/E ratio of -10.6.
P/E ratio history for NewAmsterdam Pharma Company from 2021 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -10.6 | -56.78% |
| 2021 | -24.5 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.